Showing 1–16 of 16 · Laboratory & pathology (LIMS)
Parent Danaher (DHR) group FY2025 revenue $24.57bn (+3.0%); operating margin 19.1%; net income $3.60bn.
Figures cover the whole listed group, not this business alone.
FY2025 revenue $2.58bn (+0.7%); operating margin 1.8%; net income $759.9m.
Net income lifted by non-operating investment gains; operating profit was $47m.
Recent change of ownership; current owner not yet confirmed from official filings.
Financial health not assessed until ownership and accounts are verified.
FY2025 revenue €1.21bn (+5.0%).
Revenue +5% (organic +5%). Profit figures not yet captured.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Listed (6965.T).
Latest full-year results not yet captured by HSH.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Parent Danaher (DHR) group FY2025 revenue $24.57bn (+3.0%); operating margin 19.1%; net income $3.60bn.
Figures cover the whole listed group, not this business alone.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Parent Roche (ROG.SW) group FY2025 revenue CHF 61.52bn (+2.0%); core operating margin 35.5%; net income CHF 13.80bn.
Diagnostics division sales CHF 13.85bn (+2% at constant exchange rates).
FY2025 revenue ¥500.0bn (-1.7%); operating margin 10.4%; net income ¥35.5bn.
Balance sheet figures not captured from release.
FY2025 revenue $44.56bn (+3.9%); operating margin 17.4%; net income $6.70bn.
Cash $9.85bn; debt $39.38bn.